Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis

Acta Neurologica Scandinavica

Volumn 120, Issue 2, 2009, Pages 119-122

  Ilzecka J ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Amyotrophic lateral sclerosis; Neurodegeneration; Receptor for advanced glycation end products; Serum; Soluble RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX;

EID: 67651227458     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01133.x     Document Type: Article

References (34)

1. Shibata N, Kobayashi M. The role for oxidative stress in neurodegenerative diseases. Brain Nerve 2008 60 : 157 70.
2. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002 54 : 1615 25.
3. Bucciareli LG, Wendt T, Rong L et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002 59 : 1117 28.
4. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999 84 : 489 97.
5. Ding Q, Keller JN. Evaluation of RAGE isoforms, ligands, and signaling in the brain. Biochim Biophys Acta 2005 1746 : 18 27.
6. Lue LF, Yan SD, Stern DH, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2005 4 : 249 66.
7. Wang L, Li S, Jungalwala FB. Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth. J Neurosci Res 2008 86 : 1254 66.
8. Ma L, Carter RJ, Morton AJ, Nicholson LF. RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats. Brain Res 2003 966 : 167 74.
9. Rong LL, Gooch C, Szabolcs M et al. RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor Neurol Neurosci 2005 23 : 355 65.
10. Ramsamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005 15 : 16 28.
11. Basta G, Lazzerini G, Massaro M et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002 105 : 815 22.
12. Brooks BR. El Escorial Word Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994 124 (Suppl. 96 107.
13. Gordon PH, Miller RG, Moore DH. ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord 2004 5 (Suppl 1 90 3.
14. Toth C, Martine Z, Zochodne DW. RAGE, diabetes, and the nervous system. Curr Mol Med 2007 7 : 766 76.
15. Wang Z, Li DD, Liang YY, Wang DS, Cai NS. Activation of astrocytes by advanced glycation end products: cytokines induction and nitric oxide release. Acta Pharmacol Sin 2002 23 : 974 80.
16. Lue LF, Walker DG, Brachova L et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001 171 : 29 45.
17. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007 7 : 735 42.
18. Ma L, Nicholson LF. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res 2004 1018 : 10 7.
19. Sasaki N, Takuchi M, Chowei H et al. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett 2002 326 : 117 20.
20. Yamagishi S, Adachi H, Nakamura K et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006 55 : 1227 31.
21. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006 13 : 1971 8.
22. Nakamura K, Yamagishi S, Adachi H et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007 13 : 185 9.
23. Geroldi D, Falcone C, Emanuele E et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005 23 : 1725 9.
24. Falcone C, Emanuele E, D'Angelo A et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005 25 : 1032 7.
25. Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE), soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 2007 25 : 720 5.
26. Emanuelle E, D'Angelo A, Tomaino C et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005 62 : 1734 6.
27. Sternberg Z, Weinstock-Guttman B, Hojnacki D et al. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler 2008 14 : 759 63.
28. Zhang H, Tasaka S, Shiraishi Y et al. Role of soluble receptor for advanced glycation end products on endotoxin - induced lung injury. Am J Respir Crit Care Med 2008 178 : 356 62.
29. De Palma C, Falcone S, Panzeri C, Radice S, Bassi MT, Clementi E. Endothelial nitric oxide synthase overexpression by neuronal cells in neurodegeneration: a link between inflammation and neuroprotection. J Neurochem 2008 106 : 193 204.
30. Graves MC, Fiala M, Dinglasan LA et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord 2004 5 : 213 9.
31. Reynolds A, Laurie C, Mosley RL, Gendelman HE. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 2007 82 : 297 325.
32. Babu GN, Kumar A, Chandra R, Puri SK, Kalita J, Misra UK. Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochem Res 2008 33 : 1145 9.
33. Moreau C, Devos D, Brunaud-Danel V et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology 2005 65 : 1958 60.
34. Hudson BI, Haria E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease. Arterioscler Thromb Vasc Biol 2005 25 : 879 82.